A team of scientists from McMaster University and the Massachusetts Institute of Technology has used artificial intelligence (AI) to discover a new antibiotic that could be used to treat a deadly hospital superbug.
The superbug, Acinetobacter baumannii, is a multidrug-resistant bacteria that causes a variety of infections, including pneumonia, meningitis, and bloodstream infections. It is particularly dangerous in hospitals, where it can spread easily from patient to patient.
Traditional methods of developing new antibiotics are time-consuming and expensive, and they often fail to produce new drugs that are effective against drug-resistant bacteria. However, AI can be used to screen large numbers of potential drug candidates much more quickly and efficiently than traditional methods.
In the new study, the researchers used AI to screen a library of over 100,000 potential drug candidates. They identified a new compound that they have named abduction. Abaucin is effective against A. baumannii, and it does not appear to be susceptible to the bacteria’s drug-resistance mechanisms.
The researchers are now working to develop abaucin into a new antibiotic that can be used to treat patients. If successful, abaucin could provide a new treatment option for patients with infections caused by A. baumannii.
The study was published in the journal Nature Chemical Biology.
Significance of the Study
The discovery of a new antibiotic against Acinetobacter baumannii is a significant advance in the fight against antibiotic resistance. A. baumannii is one of the world’s most dangerous drug-resistant bacteria, and it is a major cause of infections in hospitals. The development of new antibiotics against A. baumannii is essential to prevent the spread of this deadly bacteria.
The use of AI to discover new antibiotics is a promising new approach to the problem of antibiotic resistance. AI can be used to screen large numbers of potential drug candidates much more quickly and efficiently than traditional methods. This approach has the potential to accelerate the discovery of new antibiotics that can be used to treat drug-resistant bacteria.
The researchers who discovered abaucin are now working to develop it into a new antibiotic that can be used to treat patients. This process will involve further testing of abaucin in animal models of infection. If abaucin is shown to be safe and effective in animal models, it will then be tested in clinical trials. If abaucin is successful in clinical trials, it could be made available to patients in the next few years.